Tumor-suppressive role of HACE1 in hepatocellular carcinoma and its clinical significance

Gao,Zeng-Fa; Wu,Yong-Na; Bai,Zhong-Tian; Zhang,Lei; Zhou,Qi; Li,Xun

doi:10.3892/or.2016.5205

Tumor-suppressive role of HACE1 in hepatocellular carcinoma and its clinical significance

Authors:
- Zeng-Fa Gao
- Yong-Na Wu
- Zhong-Tian Bai
- Lei Zhang
- Qi Zhou
- Xun Li
View Affiliations

Affiliations: The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Gansu Province Key Laboratory of Biotherapy and Regenerative Medicine, Lanzhou, Gansu 730000, P.R. China, The Second Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Pathology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu 730000, P.R. China
Published online on: October 26, 2016 https://doi.org/10.3892/or.2016.5205
Pages: 3427-3435

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An increasing body of evidence suggests that downregulation or deletion of HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1) gene plays an important role in the occurrence, invasion and metastasis process in many human malignancies and is closely related to prognosis. However, sparse evidence exists concerning the precise function and clinical significance of HACE1 in hepatocellular carcinoma (HCC). In the present study, we investigated the expression pattern of HACE1 in HCC tissues and cell lines, and determined the potential functions of HACE1 in HCC cell lines and evaluated the relationships between HACE1 expression and clinicopathological characteristics. Protein and mRNA expression levels of HACE1 in human HCC tissues and cell lines were examined by western blot analysis, quantitative real‑time polymerase chain reaction and immunohistochemical (IHC) analyses. IHC was used to analyze the correlations between HACE1 expression and clinicopathological features. HACE1 was upregulated in SMCC7721 cells by transfection with pcDNA3.1-HACE1 and Huh7 cells were transfected with siRNA targeting HACE1 for downregulation. Cell Counting Κit-8, Transwell and wound healing assays were performed to investigate the effects of the overexpression and knockdown of HACE1 on cellular proliferation and migration. The results revealed that HACE1 expression was lower in the HCC tissues and cell lines at the mRNA and protein levels compared to levels noted in the matched non‑tumor tissues and the normal liver cell line L02. Knockdown of HACE1 in Huh7 cells accelerated cell proliferation and migration (P<0.05), and overexpression of HACE1 in SMCC7721 cells was found to decrease the capacity for proliferation and migration (P<0.01). The results of IHC suggested that the HACE1 expression level was closely related to the serum AFP level, tumor differentiation and vascular invasion (P<0.05). Patients with low HACE1 expression levels exhibited poorer overall survival and HACE1 was found to be an independent prognostic factor for survival. In conclusion, as a tumor suppressor, HACE1 may be a valuable prognostic biomarker and potential therapeutic target for HCC treatment.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Waller LP, Deshpande V and Pyrsopoulos N: Hepatocellular carcinoma: A comprehensive review. World J Hepatol. 7:2648–2663. 2015. View Article : Google Scholar : PubMed/NCBI
3	Liccioni A, Reig M and Bruix J: Treatment of hepatocellular carcinoma. Dig Dis. 32:554–563. 2014. View Article : Google Scholar : PubMed/NCBI
4	Waghray A, Murali AR and Menon KN: Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol. 7:1020–1029. 2015. View Article : Google Scholar : PubMed/NCBI
5	Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez CV, Grundy PE, Leach S, Marra MA, Brooks-Wilson AR, Penninger J, et al: Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum Mol Genet. 13:2061–2074. 2004. View Article : Google Scholar : PubMed/NCBI
6	Zhang L, Anglesio MS, O'Sullivan M, Zhang F, Yang G, Sarao R, Mai PN, Cronin S, Hara H, Melnyk N, et al: The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. Nat Med. 13:1060–1069. 2007. View Article : Google Scholar : PubMed/NCBI
7	Qu Y, Dang S and Hou P: Gene methylation in gastric cancer. Clin Chim Acta. 424:53–65. 2013. View Article : Google Scholar : PubMed/NCBI
8	Sako N, Dessirier V, Bagot M, Bensussan A and Schmitt C: HACE1, a potential tumor suppressor gene on 6q21, is not involved in extranodal natural killer/T-cell lymphoma pathophysiology. Am J Pathol. 184:2899–2907. 2014. View Article : Google Scholar : PubMed/NCBI
9	Liu Z, Chen P, Gao H, Gu Y, Yang J, Peng H, Xu X, Wang H, Yang M, Liu X, et al: Ubiquitylation of autophagy receptor Optineurin by HACE1 activates selective autophagy for tumor suppression. Cancer Cell. 26:106–120. 2014. View Article : Google Scholar : PubMed/NCBI
10	Mettouchi A and Lemichez E: Ubiquitylation of active Rac1 by the E3 ubiquitin-ligase HACE1. Small GTPases. 3:102–106. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Chen X, Sharma P, Moon M, Sheftel AD, Dawood F, Nghiem MP, Wu J, Li RK, Gramolini AO, et al: HACE1-dependent protein degradation provides cardiac protection in response to haemodynamic stress. Nat Commun. 5:34302014.PubMed/NCBI
12	Deng S and Huang C: E3 ubiquitin ligases in regulating stress fiber, lamellipodium, and focal adhesion dynamics. Cell Adhes Migr. 8:49–54. 2014. View Article : Google Scholar
13	Castillo-Lluva S, Tan CT, Daugaard M, Sorensen PH and Malliri A: The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation. Oncogene. 32:1735–1742. 2013. View Article : Google Scholar : PubMed/NCBI
14	Goka ET and Lippman ME: Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression. Oncogene. 34:5395–5405. 2015. View Article : Google Scholar : PubMed/NCBI
15	Huang Y, de Reyniès A, de Leval L, Ghazi B, Martin-Garcia N, Travert M, Bosq J, Brière J, Petit B, Thomas E, et al: Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 115:1226–1237. 2010. View Article : Google Scholar : PubMed/NCBI
16	Hibi K, Sakata M, Sakuraba K, Shirahata A, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, et al: Aberrant methylation of the HACE1 gene is frequently detected in advanced colorectal cancer. Anticancer Res 28 (3A). 1581–1584. 2008.
17	Hudson C, Schwanke C, Johnson JP, Elias AF, Phillips S, Schwalbe T, Tunby M and Xu D: Confirmation of 6q21-6q22.1 deletion in acro-cardio-facial syndrome and further delineation of this contiguous gene deletion syndrome. Am J Med Genet A 164A. 2109–2113. 2014. View Article : Google Scholar
18	Wang XC, Zhang JQ, Shen YQ, Miao FQ and Xie W: Loss of heterozygosity at 6p21.3 underlying HLA class I downregulation in gastric cancer. J Exp Clin Cancer Res. 25:115–119. 2006.PubMed/NCBI
19	Scheffner M and Kumar S: Mammalian HECT ubiquitin-protein ligases: Biological and pathophysiological aspects. Biochim Biophys Acta. 1843:61–74. 2014. View Article : Google Scholar : PubMed/NCBI
20	Stewénius Y, Jin Y, Ora I, Panagopoulos I, Möller E, Mertens F, Sandstedt B, Alumets J, Akerman M, Merks JH, et al: High-resolution molecular cytogenetic analysis of Wilms tumors highlights diagnostic difficulties among small round cell kidney tumors. Genes Chromosomes Cancer. 47:845–852. 2008. View Article : Google Scholar : PubMed/NCBI
21	Capasso M, Diskin S, Cimmino F, Acierno G, Totaro F, Petrosino G, Pezone L, Diamond M, McDaniel L, Hakonarson H, et al: Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res. 74:6913–6924. 2014. View Article : Google Scholar : PubMed/NCBI
22	Capasso M, Diskin SJ, Totaro F, Longo L, De Mariano M, Russo R, Cimmino F, Hakonarson H, Tonini GP, Devoto M, et al: Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis. 34:605–611. 2013. View Article : Google Scholar : PubMed/NCBI
23	Küçük C, Hu X, Iqbal J, Gaulard P, Klinkebiel D, Cornish A, Dave BJ and Chan WC: HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms. Am J Pathol. 182:49–55. 2013. View Article : Google Scholar : PubMed/NCBI
24	Gacon G, Mettouchi A and Lemichez E: The tumor suppressor HACE1 targets Rac1 to ubiquitin-mediated proteasomal degradatio]. Med Sci (Paris). 28:39–41. 2012.(In French). View Article : Google Scholar : PubMed/NCBI
25	Lachance V, Degrandmaison J, Marois S, Robitaille M, Génier S, Nadeau S, Angers S and Parent JL: Ubiquitylation and activation of a Rab GTPase is promoted by a β₂AR-HACE1 complex. J Cell Sci. 127:111–123. 2014. View Article : Google Scholar : PubMed/NCBI